Even though observers had widely expected some degree of success, Madrigal Pharmaceuticals, Inc. had an extremely good day on 19 December as it unveiled its long-anticipated Phase III data for resmetirom (MDGL-3196) in non-alcoholic steatohepatitis (NASH). The 955-patient Phase III MAESTRO-NASH study hit both of its primary endpoints, and as Madrigal announced plans to file resmetirom for accelerated approval during the first half of 2023, the firm’s stock price increased exponentially.
The dataset was widely lauded, with multiple analysts – while using terms like “best case,” “huge win” and “grand slam scenario” – predicting the Conshohocken, PA-based company might become a much-desired acquisition target
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?